Artículo de Revisión 29 Lima: ALEH, APEH, UPCH; 2012. p. 142-62. 53.- Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-7. 54.- Singal A, Kamath P, Gores G, Shah V. Alcoholic hepatitis: current challenges and future directions. Clin Gastroent Hepatol 2014; 12: 555-64. 55.- Palaniyappan N, Subramanian V, Ramappa V, Ryder SD, Kaye P, Aithal GP. The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway? Int J Hepatol 2012; 2012: 624675. 56.- Domínguez M, Rincón D, Abraldes JG, Miguel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103: 2747-56. 57.- Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2. 58.- Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743-6. 59.- EASL-ALEH. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-64. 60.- Louvet A, Naveau S, Abdelnour M, Ramond MJ, Díaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-54. 61.- Singal AK, Sagi S, Kuo YF, Weinman S. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. EurJ Gastroenterol Hepatol 2011; 23: 204-9. 62.- Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146: 1231-9. 63.- Yamini D, Hyunsoo S, Avanesyan A, Walter M, Runyon B. Utilization of Baclofen in Maintenance of Alcohol Abstinence in Patients with Alcohol Dependence and Alcoholic Hepatitis with or without Cirrhosis. Alcohol Alcohol 2014: 49: 453-6. 64.- Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcoholdependent subjects: secondary analysis of a randomized double-blind placebo controlled trial. Alcohol Alcohol 2011: 46: 312-7. 65.- Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis 2004; 24: 289- 304. 66.- Kang YL, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 2005; 26: 391-404. 67.- Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Eng J Med 2015; 372; 17: 1619-28. 68.- Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifyline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48. 69.- Amini M, Runyon BA. Alcoholic hepatitis 2010. A clinician’s guide to diagnosis and therapy. World J Gastroenterol 2010; 16: 4905-12. 70.- Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-62. 71.- Hadengue A. Alcoholic Steatohepatitis (ASH). En: EASL. The International Liver Congress 2012. EASL Postgraduate Course. Alcoholic Liver Disease. Barcelona; 2012. p. 103-11. 72.- Singh S, Muran MH, Chandar A, Bongiorno C, Singal A, Atkinson A, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 2015; 149: 958-70. 73.- Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-7. 74.- Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Agel B, et al. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-60. 75.- Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liv Int 2011; 31: 1432-48. 76.- Morris JM, Dickson S, Neilson M, Hosgins P, Forrest EH. Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series. Eur J Gastroenterol Hepatol 2010; 22: 457-60. 77.- Mendenhall CL, Anderson S, García-Pont P, Goldberg S, Kieman T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 1464-70. 78.- Garg V, Garg H, Khan H, Trehanpati N, Kumar A, Shama BC, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute- on-chronic liver failure. Gastroenterology 2012; 142: 505-12. 79.- Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 2011; 53: 2003-15. 80.- Singal AK, Duchini A. Liver transplantation in acute alcoholic hepatitis: current status and future development. World J Hepatol 2011; 3: 215-8. 81.- Vanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med 2009; 150: 153-61. Enfe rmedad hep ática po r alcohol - R. Lazarte C. et al. Gastroenterol. latinoam 2016; Vol 27, Nº 1: 18-30
gastro-1-2016
To see the actual publication please follow the link above